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Abstract
Rinderpest virus causes a highly contagious and often fatal disease in domestic and wild ruminants. The surface glycoproteins,
hemagglutinin (H) and fusion (F) proteins of this enveloped virus are known to confer protective immunity in cattle. We have
reported the generation of a recombinant baculovirus expressing H protein and studied its protective properties in cattle. In this
report, we demonstrate that the recombinant baculovirus encoded H protein expressed in insect cells gets incorporated into
extracellular baculovirus. Single administration of low doses of purified recombinant extracellular virus with or without adjuvant
induces virus neutralizing antibody responses and bovine leukocyte antigen (BoLA) class II restricted helper T cell responses in
cattle. © 2001 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Rinderpest, also known as ‘cattle plague’, is a highly
contagious and often fatal disease of wild and domestic
bovids with serious economic consequences. The
causative agent rinderpest virus (RPV) belongs to the
genus Morbilli6irus within the family Paramyxo6iridae
and is antigenically closely related to measles virus.
Rinderpest is prevalent in parts of Africa and Asia [1]
and the mortality rate of the disease is close to 90%.
This disease has been eradicated from the rest of the
world with the time-tested, attenuated, tissue culture
adapted rinderpest vaccine, developed by Plowright and
Ferris [2]. Though single dose vaccination confers life-
long immunity in animals, the vaccine is heat labile and
is considered to be one of the reasons for its failure in
developing countries. For the global eradication of the
disease, there is still a requirement for a heat-stable,
effective vaccine. Attempts made towards this goal
include the development of a thermostable Vero cell-
adapted rinderpest vaccine [3] and recombinant vac-
cines using vaccinia [4–10] and capripox [11,12] vectors
expressing the surface glycoproteins hemagglutinin (H)
and:or fusion (F) proteins of RPV, which are known to
confer protective immunity in animals. Recombinant
baculoviruses expressing these surface glycoproteins
have also been tested in cattle for their protective
abilities [13,14]. Involvement of cell mediated immune
responses in conferring protection against this disease
has been suggested earlier [5,13]. Recently, RPV-specific
lymphoproliferative responses were demonstrated, fol-
lowing challenge with virulent RPV, in cattle immu-
nized with a recombinant vaccinia virus expressing the
H protein [15].
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We have earlier reported the expression and charac-
terization of recombinant H protein of RPV in a mem-
brane bound form as well as a secreted soluble form
using baculovirus expression system [16] and studied
the immunogenic and protective properties of the re-
combinant baculovirus expressing the membrane bound
H protein in cattle [14]. In this report, we demonstrate
that the membrane bound form of H protein expressed
in insect cells gets incorporated into recombinant extra-
cellular baculovirus (rECV), which can be purified from
infected insect cell culture supernatant. Single adminis-
tration of low doses of purified rECV induces strong
virus neutralizing antibody response and bovine leuko-
cyte antigen (BoLA) class II restricted helper T cell
response in cattle, with or without adjuvant.
2. Materials and methods
2.1. Cell lines and 6iruses
Recombinant baculoviruses coding for a membrane
bound form of RPV-H protein (AcSNH3.41 or rECV)
and a secreted form of soluble H (SecH) have been
described earlier [16]. These viruses were propagated in
Spodoptera frugiperda (Sf) 21 insect cells grown in
insect cell culture medium TC-100 supplemented with
10% fetal bovine serum (FBS) [Gibco-BRL, USA]. Sf21
cells were infected at multiplicity of infection (MOI) 1
for 72 h and rECV released into the culture medium
was purified by sucrose density gradient ultracentrifu-
gation according to the method of Summers and Smith
[17]. Briefly, supernatants of Sf21 cells infected with
either wild type AcNPV or recombinant AcSNH3.41
were subjected to ultracentrifugation on a 25–56%
linear sucrose density gradient (100 000g for 1 h at
4°C), the virus bands were collected, diluted in sterile
ice-cold phosphate buffered saline (PBS) and pelleted
down by ultracentrifugation. The pellets were soaked
overnight at 4°C in sterile PBS and used as purified
virus stock. For production of SecH protein, Sf21 cells
were infected with the recombinant baculovirus coding
for the secreted form of H at MOI 20. The supernatant
was collected after 72 h and subjected to im-
munoaffinity purification using rabbit polyclonal anti-
bodies to H [18] coupled to CNBr activated Sepharose
4B (Pharmacia, Sweden).
Rinderpest virus (RBOK, vaccine) was obtained
from the Institute of Animal Health and Veterinary
Biologicals, Bangalore, India and was grown in Vero
cells in Minimum Essential Medium (Gibco-BRL,
USA) supplemented with 5% FBS. Titration of these
viruses by TCID50 determination was performed ac-
cording to standard methods. The virus was titrated
using TCID50 method of Reed and Muench [19].
Fig. 1. SDS-PAGE and immunoblot analysis of rECV. (1)WT-Ac-
NPV and (2) rECV (AcSNH3.41) were purified from infected S121
culture supematants by ultracentrifligation on a 25–56% linear su-
crose density gradient (l00 000g for 1 h at 37°C) according to the
method of Summers and Smith (17). 20mg of purified virus prepara-
tions were subjected to 10% SDS-PAGE and coomassie stained (a) or
immunoblotted (b) using a rabbit polyclonal serum against RPV-H
(18).
Fig. 2. ELISA reactivity of purified rECV. Indirect ELISA was
performed using purified rECV (1 mg:ml, ) and its reactivity
compared with RPV (), to (a) rabbit hyperimmune serum and (b)
cattle RPV-convalescent serum. WT-AcNPV () was used as the
non-specific antigen.
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Table 1
Humoral immune responses of rECV immunized and TCRV vaccinated cattlea
Antibody Titre (103) Weeks post-immunizationGroup Cattlec
1 2 3 4 6 16
160 25.6 40 80I 54.2RS1 51.2
80 25.6 NDRS2 20 25.6 51.2
40 ND 40 40 ND NDRS3
Antibody Titre (103) Weeks post-immunization:vaccinationGroup Cattlec
1 2 3 8 26
12 24 12II 6GS1 3
12 12 24GS2 12 6
12 12 24 12 6GS3
a ELISA titres: Cattle sera collected at different weeks p.i. were subjected to indirect BLISA using SecH as the antigen (1:20 diluted supematant
from 5121 cell culture, infected with the recombinant baculovirus expressing soluble secreted form of H [16]). Animals of group I (RS 1, RS2 and
RS3) were immunized with rECV in FCA, while in group II, GS 1 and (352 were immunized with purified rECV without adjuvant and (353 is
TCRV-vaccinated control. The highest dilution of the antiserum which showed twice the OD as that of the background was taken as the titre.
(ND-Not Determined).
2.2. SDS-PAGE analysis and immunoblotting
Purified wild type AcNPV and recombinant Ac-
SNH3.41 were subjected to 10% SDS-PAGE and the
gel was coomassie stained. A similar gel was electro-
transferred onto nitrocellulose membrane (Amersham,
USA) using LKB semidry transfer apparatus. The blot
was blocked with 2% gelatin and probed with rabbit
polyclonal antibodies against RPV-H [18] and goat-a-
rabbit IgG coupled to horse radish peroxidase (HRP)
[Gibco-BRL, USA]. H2O2 and Diaminobenzidine
(Sigma Chemicals, St Louis) were used to develop the
blot.
2.3. Vaccination:immunization of cattle
Two groups of outbred calves of approximately 1
year of age were employed in this study. In Group I,
three animals (RS1, RS2 and RS3, Jersey breed) were
immunized intramuscularly with 2 mg of purified Ac-
SNH3.41 emulsified in Freund’s Complete Adjuvant
(FCA) and one animal (RS5, Jersey breed) was vacci-
nated with one dose of RPV (RBOK) vaccine (obtained
from Institute for Animal Health, Pirbright, UK). In
Group II, two animals (GS1 and GS2, Holstein
Friesian cross breed) were immunized with 500 mg of
purified rECV in PBS without adjuvant while the third
animal (GS3, Jersey breed) served as vaccinated con-
trol. One animal (GS4, Holstein Friesian cross breed)
was used as unimmunized control animal.
2.4. Antibody assays
2.4.1. ELISA
Purified recombinant AcSNH3.41 or SecH was used
as ELISA antigen. RPV(TCRV) or wild type AcNPV
served as positive and negative control antigens respec-
tively and 2% gelatin as the blocking agent. Goat-a-
rabbit IgG (Gibco-BRL, USA), goat-a-cow IgG
(Dacopatts, Denmark) coupled to HRP, H2O2 and
o-Phenylenediamine (Sigma Chemicals, St Louis) were
used in ELISA. Competition ELISA employing mono-
clonal antibodies to H (C1 and D2F4) was performed
according to Anderson and McKay [20]. C1 Mab was
kindly provided by Dr T. Barrett, Institute for Animal
Health, Pirbright, U.K. D2F9 Mab which recognises a
linear epitope on H was generated employing sec H as
the immunising antigen and characterised in the labora-
tory (Renukaradhya et al., unpublished).
Table 2
Humoral immune responses of rECV immunized and TCRV vacci-
nated cattlea
% Inhibition of binding of C1 — Weeks
post-immunization
0 2 4
Cattlec (Group I)
22.5 45.6 58.8RS1
15.8RS2 34.8 53.6
60.938.322.7RS3
Cattlec (Group II)
20.2 72.4GS1 85.5
25.4GS2 85.1 95.3
GS3 90.824.7 82.3
a Competition ELISA: Sera collected from cattle at different time
points were subjected to competition ELISA employing monoclonal
antibodies to H (Cl or D2F4). The assay was performed and %
inhibition calculated as described earlier [19]. 1:200 diluted Ac-
SNH3.41 infected 5121 cell extract (group I) and SecH antigen (as
described above, for group II) were used as antigens. 1:5 (group I)
and 1:10 (group II) diluted cattle sera were tested for their ability to
inhibit binding of Cl (group I) or D2F4 (group II).
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Table 3
Humoral immune responses of rECV immunized and TCRV vaccinated cattlea
Virus NeutralizationTitres — Weeks post-immunization:vaccinationCattlec (Group II) Preimmune Serum
1 2 3 8 26
40 160 160 80 NDGS1 –
40 80 80– 20GS2 20
–GS3 20 40 160 80 40
GS4 –– ND – – ND
a Virus Neutralization Titres: Virus Neutralization Test (VNT) was performed according to the method of Barrett et al. [5]. Sera collected from
cattle of group II (GSl, GS2-rECV immunized, GS3-TCRV-vaccinated and GS4-unimmunized control) at different time intervals afier
immunization:vaccination were subjected to VNT to test for their ability to neutralize RPV in vitro, at various dilutions. The reciprocal of the
highest dilution of serum that showed a 50% or less CPE compared to the virus infected control well was taken as the VN titre. (ND-Not
Determined).
2.4.2. Virus neutralization test (VNT)
VNT was performed according to Barrett et al. [5].
Briefly, 100 TCID50 units of RPV was incubated with
dilutions of test sera at 37°C for 1 h and then added to
Vero cells in a flat bottomed 96-well tissue culture plate
(Costar, USA). The plate was microscopically examined
for cytopathic effect (CPE) after 3–4 days. The recipro-
cal of the highest dilution of the test serum at which the
CPE was 50% or less than that of the virus infected
control well was taken as the VN titre.
2.5. Lymphoproliferation assay
Peripheral blood mononuclear cells (PBMC) were
isolated from the experimental animals according to
standard procedure using Ficoll-Hypaque (Sigma
Chemicals, St Louis) density gradient centrifugation at
different time points after immunization. PBMC were
plated [1105 cells in 100 ml of complete RPMI 1640
medium supplemented with 10% FBS (Gibco-BRL,
USA), 50 mM b Mercaptoethanol, 1 mM Sodium pyru-
vate, 2 mM L-glutamine (Sigma Chemicals, St Louis) in
a 96-well tissue culture plate (Costar, USA)] and in
vitro stimulated with varying concentrations of extracts
of Sf21 cells infected with wild type AcNPV or recom-
binant AcSNH3.41 or purified SecH or purified bacteri-
ally expressed nucleocapsid (N) protein of RPV (Shaji
and Shaila, unpublished) in 100 ml of complete RPMI
1640 medium at 37°C with 5% CO2 in a humidified
chamber. After 5 days, the cells were pulsed with 1 mCi
[3H]-thymidine (Specific activity 6500 mCi:mmol, from
Bhabha Atomic Research Centre, Mumbai, India) for
16 h. Cells were then harvested onto GF:A glassfibre
filters (Gelman, USA) and trichloroacetic acid insoluble
radioactivity was measured in a Rackbeta liquid scintil-
lation spectrometer. The results were expressed as
counts per minute (cpm) or stimulation index (SI)
calculated as follows:
SI [Radioactivity (cpm)
incorporated in the experimental well]
} [Radioactivity (cpm)
incorporated in the medium control well]
Lymphoproliferation assays were performed in tripli-
cate wells and at least two independent experiments
were carried out. In inhibition assays, various dilutions
of hybridoma culture supernatants containing mouse
monoclonal antibodies against BoLA class II molecules
(kind gift of Dr C Howard, Institute of Animal Health,
Compton) were used.
3. Results and discussion
3.1. Recombinant H gets incorporated into ECV
particles and is antigenically authentic
When proteins present in purified wild type AcNPV
and recombinant AcSNH3.41 were subjected to SDS-
PAGE analysis, a protein band of molecular weight
70 kD was detected as an additional band in the lane
corresponding to recombinant AcSNH3.41, which is
absent in wild type AcNPV (Fig. 1a). This protein, on
immunoblotting, reacted specifically with polyclonal
antibody against RPV-H protein (Fig. 1b). This confi-
rmed that the recombinant H protein expressed in Sf21
insect cells gets incorporated into ECV. The authentic-
ity of this rECV was further confirmed in ELISA using
hyperimmune serum raised in rabbit against RPV-H
(Fig. 2a), RPV-convalescent sera from cattle (Fig. 2b)
and a conformation specific monoclonal antibody C1
(data not shown). rECV reacted very well with all these
antibodies to levels comparable to that of RPV suggest-
ing that the H protein expressed in insect cells and
subsequently incorporated into ECV particles is anti-
genically authentic.
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3.2. rECV immunized cattle generate H-specific
humoral immune responses
Sera collected from rECV immunized animals
showed RPV-H specific reactivity in indirect ELISA
when SecH was used as the antigen (Table 1). All the
Fig. 4. Specificity of lymphoproliferative responses. (a) PBMC iso-
lated from cattle of experimental group I [GS1, GS2 (rECV immu-
nized), GS3 (TCRV vaccinated) and GS4 (unimmunized control)]
were in vitro stimulated with varying concentrations of im-
munoaffinity purified SecH or purified bacterially expressed N
protein. Results at protein concentrations of 8 mg:ml for SecH or 4
mg:ml for N protein at which the proliferative responses were the
highest are represented in the figure. (b) PBMC from cattle of
experimental group I were in vitro stimulated with SecH (8 mg:ml) in
presence of varying dilutions of anti-BoLA class II antibodies. Re-
sults of a representative experiment with PBMC from GSl are pre-
sented. Stimulation index (SI) was calculated using the following
formula: SIRadioactivity (cpm) incorporated in the experimental
well:Radioactivity (cpm) incorporated in the control well.
Fig. 3. Lymphoproliferative responses of cattle PBMC to recombi-
nant H protein. (a) PBMC from cattle of group II [RS1, R53 (rECV
in FCA immunized) and RSS (TCRV-vaccinated)] were in vitro
stimulated with the recombinant baculovirus coding for the mem-
brane bound H (AcSNH3.41) infected Sf21 cell extract at the indi-
cated total protein concentrations (H corresponds to approximately
15% of the total protein in the infected cells). PBMC were stimulated
with WT-AcNPV infected Sf21 cell extract as the control antigen.
Lymphoproliferative responses to WT-AcNPV infected Sf21 cell ex-
tract at concentration 270 mg:ml which resulted in the highest stimu-
lation are represented in the figure. This assay was performed 2 years
afier immunization:vaccination of cattle. (b) PBMC isolated from
rECV immunized cattle GS1 and GS2, TCRV-vaccinated cattle GS3
and unimmunized control GS4 of group I were in vitro stimulated
with immunoaffinity (18) purified SecH at a concentration of 8 mg:ml
at different time points afier immunization:vaccination. Stimulation
index (SI) was calculated using the following formula: SIRadioac-
tivity (cpm) incorporated in the experimental well:Radioactivity
(cpm) incorporated in the control well. ND-Not Determined.
animals developed high titred antibodies against RPV-
H as early as 1 week after immunization and the
antibody levels could be detected at least upto 16 weeks
in group I and 26 weeks in group II after immuniza-
tion. Antibody titres were higher in cattle of group I.
The specificity of the antibodies was further tested
using a specific competition ELISA and these sera
showed inhibition of binding of monoclonal antibodies
C1 and D2F4 to RPV-H (Table 2). However, when sera
from rECV immunized animals were subjected to com-
petition ELISA employing a monoclonal antibody spe-
cific for RPV-N [21], there was no inhibition of binding
of this monoclonal antibody when RPV-infected Vero
cell extract was used as the antigen. As expected, sera
from vaccinated cattle showed high inhibition in this
assay (data not shown).
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The immune sera were tested for their capacity to
neutralize virus infectivity in vitro by VNT. Sera from
animals of group II were subjected to this test and high
levels of virus neutralization (VN) antibodies were de-
tected (Table 3). The levels were comparable to that
generated in vaccinated animal and VN antibodies
could be detected at least upto 26 weeks after
immunization.
3.3. H-specific and BoLA class II restricted
lymphoproliferati6e responses in rECV immunized
cattle
When the ability of PBMC from animals of group I
to proliferate in vitro in response to varying concentra-
tions of wild type AcNPV or recombinant AcSNH3.41
infected Sf21 cell extracts was tested, PBMC responded
very well to recombinant AcSNH3.41 infected Sf21 cell
extract though there were low levels of proliferation in
response to wild type AcNPV infected Sf21 cell extract.
PBMC from rECV immunized animals, RS1–RS3, re-
sponded better than vaccinated cattle, RS5, in this
assay. PBMC from all the animals exhibited the highest
proliferative response at 270 mg:ml protein concentra-
tion (Fig. 3a). This assay was performed 2 years after
the animals were immunized or vaccinated. When
PBMC from animals of group II were subjected to
proliferative assays in presence of purified SecH, the
responses could be detected in all the animals at least
for 26 weeks after immunization:vaccination. Re-
sponses were at their peak between 2–8 weeks post-im-
munization:vaccination (Fig. 3b). This response was
found to be H-specific as PBMC from rECV immu-
nized animals failed to respond N protein of RPV.
However, as expected, PBMC from vaccinated animal
proliferated in response to N protein (Fig. 4a). Further,
the lymphoproliferative responses were predominantly
BoLA class II restricted as antibodies against BoLA
class II molecules specifically inhibited antigen driven
proliferation in a dose dependent manner (Fig. 4b).
These results demonstrate that recombinant H
protein expressed in insect cells gets incorporated into
ECV particles and is antigenically authentic. Antibodies
generated in the rECV immunized animals were H-spe-
cific and could neutralize RPV infectivity in vitro.
These data suggest that H protein present on ECV
particles is ‘seen’ by the immune system as the native
RPV antigen. Further, there were long lasting H spe-
cific lymphoproliferative responses in all the immunized
animals. The cellular immune responses could be de-
tected in rECV immunized animals of group I even 2
years after immunization while in group II, the cellular
responses declined and became undetectable after 7
months although antibody responses persisted at least
for a year after immunization. This could be because
the animals of group I were immunized with higher
antigen dose in FCA. To our knowledge this is the first
demonstration of cell mediated immune responses in
cattle following immunization with one of the protec-
tive antigens of RPV. It has been demonstrated that an
inactivated recombinant vaccinia virus expressing the
rabies virus glycoprotein gene generates high levels of
rabies virus neutralizing antibodies and protects mice
and rabbits from severe challenge with rabies virus [22].
Thus, non-replicating and innocuous virus particles
have the potential to confer protection against lethal
challenges with disease causing agents. Further, rECV
particles are stable at 4°C at least upto 1 year without
apparent decrease in the titres (Naik and Shaila, un-
published observation). Moreover, as non-infectious
vaccines are generally preferred over their infectious
counterparts owing to the safety considerations, rECV
particles are a potential vaccine candidate and future
challenge experiments with virulent RPV should prove
useful in evaluating the protective efficacy of the hu-
moral and cellular immune responses generated in im-
munized animals.
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